AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01832675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine lozenge
Description: 25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
Study NCT00809159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
Study NCT02209415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT and EUS
Description: PET/CT and EUS
Study NCT01827917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Injection on day 0、7、21
Study NCT01530438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research
Description: At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...
Study NCT04450056 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01652417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Description: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Study NCT01248936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Study NCT02534064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CALIN+
Description: Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
Study NCT02534064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CALIN+
Description: Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
Study NCT01930526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
Study NCT04353336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or Hydroxychloroquine
Description: Chloroquine or Hydroxychloroquine
Study NCT00870818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
Study NCT00870818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
Study NCT00809159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AIN457
Study NCT06451393 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy with radical tumor resection surgery
Description: All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
Study NCT04180176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
Study NCT01334918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contrast
Description: Administered by intravenous infusion.
Study NCT01334918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Procedure/Surgery
Study NCT02107170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: sevoflurane-based general anesthesia
Study NCT02107170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: total intravenous anesthesia
Study NCT02107170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT00870818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
Study NCT02107170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT04042207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Glucose Predictive Suspend system
Description: consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
Study NCT04042207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBLHU System
Description: DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study NCT04042207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBLHU System
Description: DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study NCT00870818 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
Study NCT00744224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo with saline infusion
Study NCT00744224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Single dose of 80 mg prednisolone with saline infusion
Study NCT00744224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and Exenatide
Description: Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
Study NCT04014634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single GON injection with methylprednisolone
Study NCT04014634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single GON-injection with NaCl
Study NCT04418999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use
Description: Experimental
Study NCT04418999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Description: Active Comparator
Study NCT04168801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early oral refeeding
Description: Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
Study NCT04168801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: early oral refeeding
Description: Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
Study NCT01141010 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Language
Description: Plain language without psychological intervention
Study NCT01141010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language
Description: Psychological linguistic intervention will be given
Study NCT04279548 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
Study NCT04279548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
Study NCT01898741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 24 Gy in 3 fractions
Study NCT03995992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sport
Description: 10 days of sport (diving or multisport), once training per day
Study NCT03995992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sport
Description: 10 days of sport (diving or multisport), once training per day
Study NCT01367483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylnaltrexone (MNTX)
Study NCT03592069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day concomitant regimen
Description: 10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
Study NCT03592069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 day hybrid regimen
Description: 14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
Study NCT01198028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT03861364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2,4 mg/kg
Study NCT03861364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1,4 mg/kg
Study NCT00970359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process.
Study NCT02725762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LT-300 Active (PBM)
Study NCT02725762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LT-300 Inactive (Sham)
Study NCT00705328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Health Care Model (PRMHLTH)
Description: Primary health care service delivery
Study NCT00705328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreation Coordination Model (REC)
Description: Recreation coordination service delivery
Study NCT00705328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Model (COMP)
Description: a comprehensive service delivery model consisting of PRMHLTH plus REC.
Study NCT01945125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rhTSH Group
Description: Patients receiving rhTSH for RIT stimulation
Study NCT05079646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
Study NCT05079646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
Study NCT00870818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
Study NCT03968354 — intervention group
Intervention type: BIOLOGICAL
Intervention: Collection of additional blood tubes; Biobanking (plasma, liver tissue).
Description: * Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research
Study NCT04546893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study NCT04068974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210)
Description: Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
Study NCT04068974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
Study NCT01345994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: acupuncture stimulation with electricity
Study NCT02384850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
Study NCT02384850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
Study NCT02384850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
Study NCT02384850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
Study NCT04463290 — intervention group
Intervention type: OTHER
Intervention: No intervention, Patients selection based on clinical symptoms and radiological imaging
Description: No intervention
Study NCT03642353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
Study NCT03642353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
Study NCT04013113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haemoperfusion
Description: Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required.
Study NCT04013113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study NCT00870818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
Study NCT01938690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: 8 sessions of TMS followed by task specific training
Study NCT01938690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: 8 sessions of TMS followed by task specific training
Study NCT01333852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin up to 2500mg/d
Description: metformin up to 2500mg/d
Study NCT01333852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel 175mg/m² q21d
Description: paclitaxel 175mg/m² q21d
Study NCT01333852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel 175mg/m² q21d
Description: paclitaxel 175mg/m² q21d
Study NCT01333852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02863939 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single photon emission computed tomography myocardial perfusion imaging
Description: a novel cadmium-zinc-telluride (CZT) SPECT camera
Study NCT02863939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Study NCT04699552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 120W Lumenis Holmium:YAG laser 20J
Description: 120W Lumenis Holmium:YAG laser 20J
Study NCT04699552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 120W Lumenis Holmium:YAG laser 40 J
Description: 120W Lumenis Holmium:YAG laser 40J
Study NCT01334918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidetector Computed Tomography
Description: Procedure/Surgery
Study NCT04699552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 120W Lumenis Holmium:YAG laser 60 J
Description: 120W Lumenis Holmium:YAG laser 60J
Study NCT01732185 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Patient
Description: Blood and histological samples will be done at day of the inclusion.
Study NCT02471001 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Two additional blood samples will be taken from in-situ catheters during heart surgery.
Study NCT00280241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is usually administered by IV infusion over 30 minutes or longer.
Study NCT00280241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
Study NCT00280241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
Study NCT02769351 — intervention group
Intervention type: DEVICE
Intervention: periph. minimal invasive ultrafiltration
Description: ultrafiltration via a peripheral single-needle
Study NCT02489006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Study NCT02489006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Chosen by the study doctor, per standard of care.
Study NCT04013113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study NCT04013113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier).